(Q34123906)

31 July 2017

1 reference

title

Antidepressant augmentation and combinations (English)

1 reference

31 July 2017

Dording CM

1

1 reference

31 July 2017

publication date

1 December 2000

1 reference

Psychiatric Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

23

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

743-755

1 reference

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

5-HT and antidepressants: new views from microdialysis studies

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Lithium Augmentation in Antidepressant-Resistant Patients a Quantitative Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Effectiveness of Pindolol With Selected Antidepressant Drugs in the Treatment of Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Mirtazapine augmentation in the treatment of refractory depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Sodium valproate augmentation of fluoxetine or fluvoxamine effects

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Buspirone augmentation of antidepressant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

What To Do with SSRI Nonresponders?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Role of the dopaminergic system in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Psychostimulant augmentation of second generation antidepressants: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Modafinil augmentation of antidepressant treatment in depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Augmentation strategies for treatment of unipolar major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Augmentation strategies in patients with refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Refractory depression: the addition of lithium to fluoxetine or desipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Enhancement of imipramine antidepressant activity by thyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

Tricyclic Augmentation of Fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970195-7

7 January 2021

10.1016/S0193-953X(05)70195-7

Identifiers

DOI

1 reference

31 July 2017

1 reference